Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Lilly Seals Licensing Deals For Olumiant, What Next For Challenger Natco?

Executive Summary

Lilly signs licensing pacts with Cipla, Sun and Lupin for baricitinib in COVID-19, with possibly more in store. But will challenger Natco, which has apparently already rolled out its cut-price version of the JAK inhibitor, change tack amid the Indian government's mixed position on compulsory licensing issues in an ongoing court case?

You may also be interested in...



Can JAK Inhibitors Save Lives From COVID-19? Pfizer Might Let RECOVERY Answer The Question

Pfizer has unveiled promising results from a study of Xeljanz but needs a bigger trial. Given RECOVERY’s track record, the pharma company may opt to wait for its results.

Asia Deal Watch: Heartseed Licenses Lead Cell Therapy Candidate To Novo Nordisk

Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.

Deal Watch: Roche To Try Pieris’s Anticalins In Respiratory, Ophthalmic Indications

Pieris and Genentech try partnering again after a disappointing IO tie-up before. Biogen’s hectic May includes partnerships with Ginkgo, Envisagenics, Capsigen and an opt-in on TMS’s stroke candidate.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel